PACS Group (PACS) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 29.1% year-over-year to $981.8 million, with adjusted EBITDA up 77% to $99.7 million, reflecting strong operational execution, high occupancy, and expansion through acquisitions.

• Operates 220 facilities across 9 states as of June 30, 2024, serving over 22,000 patients daily, supported by ~35,000 employees, and expanded to 248 operated facilities post-Q2.

• Completed IPO in April 2024, raising $414.2 million in net proceeds, with $90.9 million in stock-based compensation impacting Q2 net income.

• Major acquisitions included 3 Kansas facilities and the Prestige transaction (53 facilities across 8 states), expanding the footprint to 276 facilities in 15 states.

• Mature facilities achieved 94.2% occupancy and a 4.3 average QM star rating, outperforming industry averages.

Financial highlights

• Q2 2024 revenue was $981.8 million, up 29.1% year-over-year; six-month revenue reached $1.92 billion, up 30.5%.

• Q2 2024 adjusted EBITDA was $99.7 million, up from $56.4 million in Q2 2023; six-month adjusted EBITDA was $188.2 million.

• Q2 2024 GAAP net loss of $10.9 million, primarily due to IPO-related stock-based compensation; six-month net income was $38.2 million.

• Cash and available liquidity as of June 30, 2024: $413.8 million; cash and cash equivalents: $73.4 million.

• Average Medicare daily rates increased 9.5% year-over-year; Medicaid rates up 3.5%.

Outlook and guidance

• 2024 annual revenue guidance raised to $3.85–$3.95 billion, representing ~25% growth over 2023.

• 2024 adjusted EBITDA guidance increased to $370–$380 million.

• Management expects continued revenue growth through acquisitions and operational improvements, with robust M&A pipeline.